Kidney and Blood Pressure Changes in Patients Receiving Bevacizumab, Aflibercept, Sunitinib, or Cediranib for Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00691730
Recruitment Status : Active, not recruiting
First Posted : June 5, 2008
Last Update Posted : November 8, 2017
National Cancer Institute (NCI)
Information provided by (Responsible Party):
University Health Network, Toronto

No Study Results Posted on for this Study
  Recruitment Status : Active, not recruiting
  Actual Primary Completion Date : June 2012
  Estimated Study Completion Date : December 2018